Sulfonylureas: the role and place of drugs in the management of type 2 diabetes mellitus

• Alexander S. Ametov
• Natalya A. Chernikova
• Knyshenko Olga A.

Abstract

Nowadays there are 4.5 million patients with diabetes in Russia, and 92.1% of cases are type 2 diabetes mellitus. According to the Federal Register of Diabetic Patients, only 75.2% of them take glucose-lowering therapy. Despite the rapid development of diabetology and the emergence of new innovative classes of glucose-lowering drugs, sulfonylurea drugs (SUs) occupy an important place in the modern management of type 2 diabetes. First of all, this is due to the pathogenetic mechanism of action, well-studied pancreatic and extrapancreatic effects and its adequate cost. According to the data of the Russian Federation and other countries, the most common variant of glucose-lowering therapy is a combination of metformin and SUs.

Keywords:type 2 diabetes mellitus, sulfonylureas, ischemic preconditioning, nephroprotection, cardioprotection, CYP2C9, polymorphism

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)